Aurobindo Pharma Ltd.
Research Aurobindo Pharma Ltd. (AUROPHARMA.NS) on Bullrun: market cap INR 959.10B, P/E 26.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAUROPHARMA.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 959.10B
- P/E26.0
- Financial periodQ2 2026
- RevenueINR 91.06B
- Net incomeINR 10.33B
- Gross margin60.2%
Valuation Snapshot
latest market cap is INR 959.10B; P/E is 26.0.
Peer valuation comparison
Latest P/E is 26.05x versus a Healthcare sector median of 21.74x (19.8% above).
Latest P/E is 26.05x versus a India median of 34.43x (24.3% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 959.10B | 26.0 | n/a | 4 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 4 INR.
About Aurobindo Pharma Ltd.
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aurobindo Pharma Ltd.'s market cap?
Aurobindo Pharma Ltd.'s market capitalization is INR 959.10B.
What is Aurobindo Pharma Ltd.'s P/E ratio?
Aurobindo Pharma Ltd.'s price-to-earnings (P/E) ratio is 26.0.
What does Aurobindo Pharma Ltd. do?
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas.